Clinical Stabilization of Hypercapnia: NIPPV v HVNI
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chronic Obstructive Pulmonary Disease
- Dyspnea
- Hypercapnic Acidosis
- Hypercapnic Respiratory Failure
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The overall objective of this randomized study is to evaluate the efficacy of HVNI, in comparison to NIPPV, to clinically stabilize and provide respiratory therapy to patients who have COPD with moderate-to-severe hypercapnic respiratory distress upon presentation. It is hypothesized that HVNI is co...
The overall objective of this randomized study is to evaluate the efficacy of HVNI, in comparison to NIPPV, to clinically stabilize and provide respiratory therapy to patients who have COPD with moderate-to-severe hypercapnic respiratory distress upon presentation. It is hypothesized that HVNI is comparable to NIPPV in the stabilization and relief of moderate-to-severe hypercapnic respiratory distress upon presentation, by relieving the patient's dyspnea (breathlessness) within 4 hours to a comparable degree to NIPPV.
Tracking Information
- NCT #
- NCT04709562
- Collaborators
- Erlanger Baroness Hospital
- The Cooper Health System
- Dignity Health - St. John's Regional Medical Center
- Investigators
- Principal Investigator: Jessica Whittle, MD, PhD, FACEP Erlanger Health System, University of Tennessee School of Medicine Principal Investigator: Christopher W Jones, MD The Cooper Health System Principal Investigator: Anthony Innabi, MBA, RRT-NPS Dignity Health - St. John's Regional Medical Center
Get Well Soon